|
Chronic Myeloid Leukemia News Feed
|
Latest Chronic Myeloid Leukemia News and Research
|
-
Novartis' Gleevec receives FDA approval for use in patients with CD117-positive GIST
The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors.
-
Kedem commences development of Gleevec to treat CML in children and adults
Kedem Pharmaceuticals Inc., a specialty pharmaceutical company with focus on sublingual drug delivery system is pleased to announce that has initiated the development of Gleevec.
-
Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting
Researchers from the John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, presented results from 31 major studies of blood-related cancers - leukemia, lymphoma and multiple myeloma -- during the American Society of Hematology (ASH) Annual Meeting, December 10-13, 2011 in San Diego.
-
NYUCI experts present latest research findings about hematologic cancers at 53rd ASH meeting
Experts from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, presented their latest research findings about hematologic cancers at the 53rd ASH Annual Meeting and Exposition held December 10-13, 2011 in San Diego, California.
-
Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH
Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.
-
John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting
The John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 31 cutting-edge studies at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego from December 10-13.
-
New method reveals complete set of aberrant signaling pathways that give rise to cancers
One major obstacle in the fight against cancer is that anticancer drugs often affect normal cells in addition to tumor cells, resulting in significant side effects. Yet research into development of less harmful treatments geared toward the targeting of specific cancer-causing mechanisms is hampered by lack of knowledge of the molecular pathways that drive cancers in individual patients.
-
New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting
Pfizer Oncology will present data on a number of investigational compounds from its hematology portfolio, including new data from bosutinib in chronic myeloid leukemia (CML), inotuzumab in non-Hodgkin lymphoma (NHL), as well as the first presentation of clinical data for PF-04449913, which inhibits Smoothened (SMO), a key component of the Hedgehog pathway.
-
Asuragen introduces ARQ IS Calibrator Panels to improve BCR-ABL1 testing for CML
Asuragen, Inc. announced today that it has commercially launched the ARQ IS Calibrator Panels (RUO), intended to aid laboratories with standardization of BCR-ABL1 quantitative measurements on the International Scale.
-
Long-term results from ARIAD's ponatinib Phase 1 study on CML and Ph+ ALL
ARIAD Pharmaceuticals, Inc. today announced long-term results of the Phase 1 study of its investigational pan-BCR-ABL inhibitor, ponatinib, in heavily pretreated patients with resistant and refractory chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia.
|